Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
Despite sustained efforts to reduce opioid-related overdose fatalities, rates have continued to rise. In many areas, overdose response involves emergency medical service (EMS) personnel administering naloxone and transporting patients to the emergency department (ED). However, a substantial number of patients decline transport, and many EDs do not provide medication for opioid use disorder (MOUD). One approach to filling this gap involves delivering MOUD to overdose patients in the field with trained post-overdose EMS teams who can initiate buprenorphine. (Source: Journal of Substance Abuse Treatment)
Source: Journal of Substance Abuse Treatment - April 14, 2024 Category: Addiction Authors: Charles Beldena, Albert Kopaka, Courtney Coulesa, Tessa Friesena, Justin Hallb, Shuchin Shuklaa Source Type: research
Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes
CONCLUSIONS: Extended-release buprenorphine with steady drug concentration seems to be a promising pharmacotherapy option during pregnancy for mothers. Maternal health during pregnancy may contribute to the well-being of newborns. Larger trials are urgently needed to confirm these results..PMID:38608352 | DOI:10.1016/j.ejogrb.2024.04.003 (Source: Reproductive Biology)
Source: Reproductive Biology - April 12, 2024 Category: Reproduction Medicine Authors: Minna Kanervo Sarimari Tupola Eeva Nikkola Krista Rantakari Hanna Kahila Source Type: research
Characterization of peer support services for substance use disorders in 11 US emergency departments in 2020: findings from a NIDA clinical trials network site selection process
CONCLUSIONS: The majority of ED-based PSSs were funded through time-limited grants, and short-term grant funding was identified as a barrier for ED PSS programs. There was consistency among sites in the involvement of PSSs in facilitation of transitions of SUD care, coordination of follow-up after ED discharge, and PSS involvement in naloxone distribution.PMID:38589934 | DOI:10.1186/s13722-024-00453-x (Source: Addiction Science and Clinical Practice)
Source: Addiction Science and Clinical Practice - April 8, 2024 Category: Addiction Authors: Lindsey K Jennings Laura Lander Tricia Lawdahl Erin A McClure Angela Moreland Jenna L McCauley Louise Haynes Timothy Matheson Richard Jones Thomas E Robey Sarah Kawasaki Phillip Moschella Amer Raheemullah Suzette Miller Gina Gregovich Deborah Waltman Kath Source Type: research
Characterization of peer support services for substance use disorders in 11 US emergency departments in 2020: findings from a NIDA clinical trials network site selection process
CONCLUSIONS: The majority of ED-based PSSs were funded through time-limited grants, and short-term grant funding was identified as a barrier for ED PSS programs. There was consistency among sites in the involvement of PSSs in facilitation of transitions of SUD care, coordination of follow-up after ED discharge, and PSS involvement in naloxone distribution.PMID:38589934 | PMC:PMC11003047 | DOI:10.1186/s13722-024-00453-x (Source: Addiction Science and Clinical Practice)
Source: Addiction Science and Clinical Practice - April 8, 2024 Category: Addiction Authors: Lindsey K Jennings Laura Lander Tricia Lawdahl Erin A McClure Angela Moreland Jenna L McCauley Louise Haynes Timothy Matheson Richard Jones Thomas E Robey Sarah Kawasaki Phillip Moschella Amer Raheemullah Suzette Miller Gina Gregovich Deborah Waltman Kath Source Type: research
Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
ConclusionsThese findings can help improve provider-, clinic-, and system-level supports for MOUD prescribing across multiple settings, as well as foster communication strategies that can increase patient acceptance of MOUD. They also point to how interprofessional collaboration across service lines and leadership support can facilitate MOUD prescribing among non-addiction providers. (Source: Journal of General Internal Medicine)
Source: Journal of General Internal Medicine - April 8, 2024 Category: Internal Medicine Source Type: research
Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial
CONCLUSIONS: Past 24-hour craving was associated with increased next-week opioid use; however, craving only partially mediated the effect of buprenorphine/naloxone and methadone on next-week opioid use. Research is needed to develop a comprehensive understanding of factors mediating opioid use during opioid agonist therapy.PMID:38579594 | DOI:10.1016/j.addbeh.2024.108023 (Source: Addictive Behaviors)
Source: Addictive Behaviors - April 5, 2024 Category: Addiction Authors: Christina McAnulty Gabriel Bastien Omar Ledjiar M Eugenia Socias Bernard Le Foll Ron Lim Didier Jutras-Aswad OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: Primary Care)
Source: Primary Care - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial
CONCLUSIONS: Past 24-hour craving was associated with increased next-week opioid use; however, craving only partially mediated the effect of buprenorphine/naloxone and methadone on next-week opioid use. Research is needed to develop a comprehensive understanding of factors mediating opioid use during opioid agonist therapy.PMID:38579594 | DOI:10.1016/j.addbeh.2024.108023 (Source: Addictive Behaviors)
Source: Addictive Behaviors - April 5, 2024 Category: Addiction Authors: Christina McAnulty Gabriel Bastien Omar Ledjiar M Eugenia Socias Bernard Le Foll Ron Lim Didier Jutras-Aswad OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
Prim Care Companion CNS Disord. 2024 Apr 2;26(2):23br03659. doi: 10.4088/PCC.23br03659.NO ABSTRACTPMID:38579268 | DOI:10.4088/PCC.23br03659 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - April 5, 2024 Category: Primary Care Authors: Abid Rizvi Christina L Nolte Paramjit Chumber Deep Yadava Issaiah Wallace Amit Jagtiani Source Type: research
Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
CONCLUSIONS: Ongoing depressive symptoms lead to poorer outcomes in POUD. Clinicians are encouraged to use integrative approaches to optimize treatment outcomes. This study was registered in ClinicalTrials.gov (NCT03033732) on January 27th, 2017, prior to participants enrollment.PMID:38580298 | DOI:10.1080/15504263.2024.2329267 (Source: Journal of Dual Diagnosis)
Source: Journal of Dual Diagnosis - April 5, 2024 Category: Addiction Authors: Gabriel Bastien Anita Abboud Christina McAnulty Laurent Elkrief Omar Ledjiar M Eugenia Socias Bernard Le Foll Anees Bahji Suzanne Brissette St éphanie Marsan Didier Jutras-Aswad Source Type: research
